Evidence map›Paper›PMID 40470327›Full record

ArticleInnovation (Cambridge (Mass.))2025

Novel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming.

Suyao Li, Wenrui Zhao, Quanlin An, Lei Wang, Mengxuan Zhu, Junjie Ni, Xuan Huang, Yudong Jiang, Min Li, Jiayun Hou and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Innovation (Cambridge (Mass.)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. From mono- to multi-cellularFrontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Suyao LiDepartment of Medical Oncology, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Wenrui ZhaoInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Quanlin AnInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Lei WangDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Mengxuan ZhuDepartment of Medical Oncology, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Junjie NiInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Xuan HuangInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yudong JiangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 20032, China.
Min LiInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jiayun HouInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yiyi YuDepartment of Medical Oncology, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Shan YuDepartment of Medical Oncology, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Lai WeiInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Heng JiaoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 20032, China.
Tianshu LiuDepartment of Medical Oncology, Shanghai Key Laboratory of Oncology Target Discovery and Antibody Drug Development, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Xin CaoInstitute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced colorectal cancer (CRC) exhibits weak responses to multiple therapies, primarily due to the presence of cancer stem cells (CSCs), which drive high recurrence rates, metastasis, and drug resistance. We have previously systematically conducted CSC-targeted compound discovery and evaluation studies to inhibit CSC-mediated tumorigenesis and metastasis. Here, we identified ZSH-512, a novel synthetic retinoid that selectively targets retinoic acid receptor (RAR)γ, demonstrating its ability to effectively inhibit CRC-CSCs and patient-derived organoids (PDOs)

Indexed as

cancer stem cellcolorectal cancerepigenetic reprogrammingKDM3Aretinoidtumor-repopulating cellZSH-512

Identifiers

PMID40470327
PMCPMC12130993

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.